Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vial

Explore full profile

A tech-enabled CRO delivering superior clinical trial outcomes

San Francisco, United StatesFounded 2020Biotech & Life Sciences
Valuation $250–500M Last recorded · 2022
Revenue $10–50M Latest reported FY
Headcount 100–500 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Vial and the history behind them.

About Vial

Vial.com is a technology-driven Contract Research Organization (CRO) that operates in the global clinical trials market. Its mission is to empower scientists to cure all human diseases by delivering faster and more efficient trials. The company serves clients in the pharmaceutical and biotechnology sectors, helping them conduct clinical trials more efficiently and at a larger scale.

Vial.com's business model revolves around its proprietary Vial Technology Platform. This platform uses connected systems and intuitive design to streamline the clinical trial process, moving it away from traditional paper-based methods. The platform allows for seamless transitions between different visits and phases of a trial, redefining how these trials are conducted.

The company also offers a fixed-fee pricing model, which helps clients maximize their return on investment (ROI). This means that clients pay a set price for the service, regardless of the time and resources it takes to complete the trial. This model provides cost certainty for clients and incentivizes Vial.com to conduct trials as efficiently as possible.

Vial.com also provides thought leadership in the industry, publishing white papers on topics such as the future landscape of dermatology clinical trials and best practices for patient recruitment in oncology.

In summary, Vial.com is a technology-driven CRO that uses its proprietary platform to conduct clinical trials more efficiently and at a larger scale. It serves clients in the pharmaceutical and biotech sectors and operates on a fixed-fee pricing model.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
San Francisco, United States
Employees
161
Open positions
7
Dealroom signal
63.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Hard Tech
Business model
Marketplace & ecommerce
Client focus
b2b

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Dec 2022 $67M $268M Adam Rothenberg · David Tisch · Hemant Taneja · Zak Kukoff ↗
SEEDOther financing Apr 2021 $0 — Buckley Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Vial website traffic

Latest recorded traffic for Vial is 11K monthly website visits, up 0% over the last three months. Vial's team declined 8% over the past year.

Latest monthly visits11K 3-month web change0% 1-year team growth-8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

22 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Buckley Ventures

Series A21 investors entered at this stage

  • Adam Rothenberg
  • David Tisch
  • Hemant Taneja
  • Zak Kukoff
  • Josh Buckley
  • Greg R. Meland
  • TJ Nahigian
  • Byers Capital
  • General Catalyst
  • BoxGroup
  • Blake Byers
  • Dan Ashton
  • JD Ross
  • Jeff Silverstein
  • Elena Viboch
  • Gordon Wintrob
  • Connor Zwick
  • Nikhil Krishnan
  • David Hsu
  • Nimi Katragadda
  • Spike Lipkin
Team profiled 17 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
10 countries with
team presence
🇺🇸 United States44%
🇨🇦 Canada26%
🇦🇺 Australia12%
🇨🇱 Chile4%
🇧🇩 Bangladesh2%
Top 5 of 10 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vial on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vial’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.